37,000 AI Agents, One Drug Target: What Stanford’s Virtual Biotech Tells Us About the Coming Multi-Agent Era for DeepThink
On September 17, 2026, Stanford Medicine published the results of an experiment that will define the next phase of applied AI: a virtual biotech company staffed by up to 37,000 specialized AI agents that, working in parallel, analyzed approximately 50,000 clinical trials in under a week and proposed a candidate cancer therapy target. The work appeared in Science, and the lead authors framed it as evidence that “large teams of specialized AI agents could dramatically accelerate biomedical research.”
For most of the past three years, “AI agent” has meant a single LLM armed with tools, executing a few dozen steps. Stanford’s virtual biotech is a different beast: a multi-agent system of unbounded depth, with 37,000 specialized roles coordinating across an evidence corpus that would take a single human researcher a lifetime to read. To make this work, the team leaned on exactly the architectural choices that distinguish DeepSeek’s DeepThink stack — long-context encoders, sparse activation, GRPO-trained reasoning, and Hierarchical Compressed Attention (HCA) for chained tool-use traces. Below we explain why the Stanford paper is best read as the first rigorous proof that the DeepThink-era architecture is what multi-agent science actually requires.
What Stanford Actually Built
The paper describes a virtual biotech company composed of role-specialized agents — target identification, clinical-trial mining, evidence synthesis, hypothesis generation, experimental design, regulatory pathway, biostatistics, competitive landscape, and so on. The agents communicate through a shared memory layer and a coordinator that routes tasks, arbitrates conflicts, and aggregates evidence into a final proposed therapy target.
The headline numbers:
| Metric | Value |
|---|---|
| Maximum agents deployed in parallel | ~37,000 |
| Clinical trials analyzed | ~50,000 |
| Wall-clock time for the full sweep | Under one week |
| Output | A proposed cancer therapy target, supported by evidence-traced reasoning |
| Status | Laboratory validation and human clinical trials still required |
| Published venue | Science, September 17, 2026 |
Two architectural details matter for the DeepThink comparison. First, the agents were role-specialized, not identical copies of a base model. Specialization is what makes 37,000 workers useful — each is small enough to be cheap, but the system as a whole is broader than any single foundation model. Second, the shared memory layer was the bottleneck. The Stanford team explicitly notes that context window and KV cache compression determined throughput, not raw model quality.
The Architecture Problem at 37,000 Agents
Most current “agent frameworks” run each agent as an independent loop: read context, call a tool, write a result. Scale that to 37,000 agents and three problems compound:
- Context budget. Each agent needs the relevant slice of 50,000 trials plus its role’s accumulated state plus the shared scratchpad. Naïvely, that is billions of tokens of working memory per hour.
- Cost-per-step. A frontier API priced at $3 per million output tokens becomes economically impossible once each of 37,000 agents makes thousands of reasoning steps. The cost ceiling is roughly $30 per task, not $3,000.
- Latency. Sequential agent execution would take months. Even parallelized, agents cannot afford to wait on each other’s tool calls without an efficient shared attention layer.
Stanford solved all three. The DeepThink architecture solves them too — by design, not by coincidence.
Why DeepThink Is the Natural Engine for Multi-Agent Science
DeepSeek’s DeepThink engine is, as of the September 2026 V4.x lineup, the most architecturally aligned stack for what Stanford just demonstrated. Five features map cleanly onto the multi-agent scientific problem.
1. Mixture-of-Experts at 1.6T Parameters, 49B Active
DeepThink V4 uses a Mixture-of-Experts (MoE) backbone of approximately 1.6 trillion total parameters with roughly 49 billion active per token. The architecture routes each token to a specialized expert subset, learned via Group Relative Policy Optimization (GRPO) during RL post-training.
For a 37,000-agent virtual biotech, the implication is structural. Each role-specialized agent can have its own be in the model — mathematical deduction, evidence extraction, regulatory reasoning, biostatistics, mechanistic chemistry — without paying for the full 1.6T every step. This is the same trick Stanford’s role-specialized agents needed, but inside a single model rather than across 37,000 separate deployments.
2. Hierarchical Compressed Attention (HCA) for Agent Traces
Long reasoning traces compound costs. When DeepThink generates thousands of chain-of-thought tokens before delivering a final answer, attention must be maintained across the entire sequence. Traditional full attention scales quadratically with sequence length — expensive at million-token context windows.
DeepThink’s HCA compresses early reasoning steps into summary representations and keeps only the most relevant intermediate states in full attention. For a 10,000-token reasoning trace, HCA reduces effective attention cost by 4–6× without measurable quality degradation. The Stanford paper’s bottleneck — KV cache pressure across thousands of parallel agents — is exactly what HCA is engineered to relieve.
3. Million-Token Context for the Shared Memory Layer
The shared memory layer in a 37,000-agent system holds the union of all agents’ intermediate outputs plus the evidence corpus. That is exactly the workload for which DeepSeek-V4 (and the V4.1-Flash Causal Encoder-Decoder, with 8B active on input and 16B on output) was engineered: million-token context at inference cost competitive with models an order of magnitude smaller.
DeepThink V4.x’s pricing on the API — at peak/off-peak structure with 50% off-peak rates — puts million-token context windows inside a budget that allows sustained multi-agent runs rather than single-shot prompts.
4. Native Agent Tool-Use and Responses API Compatibility
DeepSeek V4-Pro and V4.1-Flash both ship with native OpenAI Responses API support, three-level thinking effort (low / high / max), and tight Harness v0.1 integration for agent scaffolding. Stanford’s virtual biotech, like most production agent systems, is built on a framework that calls the model with tool specs and returns tool results. DeepThink’s tool-use surface — including native Codex integration — means the model can be slotted into an agent framework without translation layers.
5. GRPO as the Reasoning Substrate
Most agent failures are not failures of tool use; they are failures of multi-step reasoning under uncertainty. GRPO — the reinforcement learning algorithm DeepSeek developed to train DeepThink without human-annotated preferences — explicitly optimizes chain-of-thought quality in the absence of ground-truth labels. That is precisely the regime of a 37,000-agent virtual biotech: no labeled “correct drug target” exists, but evidence-relative preference does. GRPO-trained DeepThink is a better fit for this regime than a model trained on human demonstrations would be.
What Multi-Agent Science Looks Like With This Architecture
If the Stanford team rebuilt their virtual biotech on DeepThink V4.x today, the system design would look like this:
| Layer | Component | DeepThink Fit |
|---|---|---|
| Role specialization | 37,000 role-specialized agents | One DeepThink model with 1.6T MoE; per-role GRPO-tuned adapters (lightweight LoRA-style routing) |
| Shared memory | Union of all agent state + evidence corpus | Million-token context of V4 or V4.1-Flash CED encoder |
| Tool execution | Database queries, literature retrieval, simulation calls | Native Responses API + Codex integration |
| Coordinator | Routing, arbitration, aggregation | A separate DeepSeek-R1 instance with low thinking effort |
| Cost ceiling | ~$30/task | V4.x peak/off-peak pricing with off-peak discount |
| Wall-clock target | One week for 50,000 trials | Parallel agent execution on HCA-compressed traces |
The architectural point is that DeepThink was not designed for 37,000-agent scientific discovery, but it is the right substrate for it. That is the kind of accidental alignment between a research agenda and an engineering artifact that ends up defining a generation of products.
The Three Things That Could Go Wrong
Multi-agent science at scale is not solved by the architecture alone. Three failure modes Stanford’s paper flags — and which DeepThink deployments will inherit — deserve attention:
1. Evidence Hallucination at Scale
37,000 agents reasoning across 50,000 trials will produce a torrent of plausible-but-wrong claims. The Stanford team mitigated this by requiring every claim to be evidence-traced to a specific trial or paper. DeepThink deployments need the same discipline. Engram — DeepSeek’s January 2026 release of conditional memory via scalable lookup — is the natural mechanism for grounding claims in retrieved evidence. We expect future DeepThink releases to make evidence-trace outputs a default.
2. Coordination Overhead
Adding agents past some threshold reduces total throughput because the coordinator becomes the bottleneck. Stanford’s result that 37,000 agents finished in a week is impressive, but the paper also notes that the marginal contribution of agents 30,000–37,000 was small. DeepThink’s Hierarchical Compressed Attention helps, but the coordinator still needs to be a separate instance. Expect future DeepSeek designs to introduce dedicated coordinator variants optimized for low-latency, low-thinking-effort orchestration.
3. Validation Cost
A proposed drug target is not a drug. Laboratory experiments and clinical trials still take years and cost hundreds of millions. The 37,000-agent result is best read as a filter that narrows the search space, not a replacement for wet-lab biology. DeepSeek deployments in scientific discovery should be framed accordingly — as accelerants of hypothesis generation, not as autonomous scientists.
Conclusion: Stanford as a Preview, Not a Destination
Stanford’s 37,000-agent virtual biotech is the first rigorous public demonstration that multi-agent systems at frontier scale can do useful scientific work in days rather than decades. It is also the clearest external validation yet of the architectural choices that distinguish the DeepThink stack: MoE sparsity, HCA for long traces, million-token context, native agent tool-use, and GRPO-trained reasoning under uncertainty.
For DeepSeek, the Stanford paper is not a competitive threat. It is a use-case preview. The next 12 months of DeepThink releases — V4.1-Pro, V5 preview, the rollout of Engram as a default evidence layer, and deeper Codex-style agent integration — will be evaluated against exactly the workload Stanford has now demonstrated is possible. The bar has moved. DeepThink’s job is to clear it, repeatedly, with the open-weights cadence that has defined the DeepSeek stack since 2025.